ORDER A TEST Log In Contact Us
Back TO GENOMIC PROFILING

xMPortfolio of Minimal Residual Disease & Monitoring

Our portfolio of tumor-naive and tumor-informed minimal residual disease (MRD) and monitoring assays provides physicians with valuable patient insights to individualize treatment plans.

xM is a finely tuned MRD assay that delivers rapid results from one blood draw to help detect residual disease or recurrence in colorectal cancer.

xM (NeXT Personal® Dx)* is an ultra sensitive, whole genome MRD and monitoring assay that enables detection of ctDNA at very low levels in NSCLC, breast cancer and for IO treatment response monitoring.

*Test by Personalis

LEARN MORE

xM is a tumor-naive, finely tuned assay

ASSAY DESIGN

xM was developed using Tempus’ multimodal database and advanced machine learning algorithms to help accurately detect and classify tumor fragments from non-tumor fragments.

Cancer Indications

Stage II-III colorectal cancer patients

Tumor-naive approach

xM is a blood-based assay that can be seamlessly integrated into a patient’s routine blood draw schedule, minimizing the burden to clinical practices.

Results

Binary ctDNA status call (detected/not detected)

image description

xM (NeXT Personal® Dx) is a tumor-informed, ultra-sensitive whole genome assay

ASSAY DESIGN

xM (NeXT Personal® Dx) is an ultra-sensitive personalized MRD assay, capable of detecting molecular markers at concentrations as low as 1.67 parts per million (PPM). It utilizes whole genome sequencing to identify up to 1800 somatic variants, filtering out confounding factors such as CHIP and germline variants through a tumor normal matched approach.

Cancer Indications

Stage IA–IIIB NSCLC patients

Stage II–III breast cancer patients

IO monitoring for pan solid tumors

Tumor-informed approach

xM (NeXT Personal® Dx) utilizes a tumor-informed methodology and provides a personalized assessment of residual disease based on information specific to the patient’s tumor DNA.

results

Binary ctDNA status call (detected/not detected) and quantitative results

Detection of ctDNA may function as an early indicator for recurrent malignancy, prior to being seen on radiographic scans.

xM CLINICAL PERFORMANCE IN COLORECTAL CANCER1

From a subset analysis from the GALAXY study in CIRCULATE-Japan, xM results predict disease-free survival (DFS) nearly 5 times superior to standard of care carcinoembryonic antigen (CEA).

image description

xM (NeXT Personal® Dx) CLINICAL PERFORMANCE IN NSCLC2

As observed in a study in early stage NSCLC, 94% of patients that recurred were detected with xM (NeXT Personal® Dx), and 89% of patients that were negative throughout longitudinal testing did not recur with a median follow up of 5 years*.

image description

Improving your workflows

Tempus offers a variety of options to customize MRD testing for patients.

ORDERING FLEXIBILITY

Place a single MRD order or a series of longitudinal orders, based on a cadence you determine is medically necessary.

image description

MOBILE PHLEBOTOMY

We want to make blood draw services as convenient as possible for your patients who are unable to come into typical clinical/hospital settings.

To schedule an appointment, please call 800.739.4137 or utilize the Mobile Phlebotomy Request Form.

image description

TEMPUS HUB

Order and view results through our AI-enabled online platform. Paper requisition and EHR ordering are also available.

Access Tempus Hub
image description

Resources

view all RESOURCES
  • UPCOMING WEBINAR:

    2024 ASCO® Annual Meeting: Colorectal Cancer Data

    Read more
  • UPCOMING WEBINAR:

    2023 ESMO Congress: NSCLC Data Data

    Read more
  • UPCOMING WEBINAR:

    2024 ASCO® Annual Meeting: Breast Cancer Data

    Read more
  • UPCOMING WEBINAR:

    2024 ASCO® Annual Meeting: IO Monitoring Data

    Read more
Financial Assistance

We help provide access to our tests for all patients in financial need.

Approval of the financial assistance application is based on your household income and takes into account all life circumstances. Once a financial assistance application is submitted either online or over the phone, you will receive a decision at the time of submission. 

  • Step 1

    Apply for financial assistance online at access.tempus.com.

  • Step 2

    If approved, you will know immediately about the maximum out-of-pocket cost of your testing.

  • Step 3

    Please contact billing@tempus.com if you are concerned about out-of-pocket costs and would like to discuss your options.

All U.S.-based patients are eligible to apply for financial assistance regardless of insurance status. For uninsured and international patients, we offer a self-pay option. If you have any questions, please email patients@tempus.com.
  1. Nakamura Y, Kaneva K, Lo C, et al. Longitudinal clinical performance of a novel tumor-naive minimal residual disease assay in resected stage II and III colorectal cancer patients: A subset analysis from the GALAXY study in CIRCULATE-Japan. Poster presented at: American Society of Clinical Oncology Annual Meeting; May 31-June 4, 2024; Chicago Illinois.
  2. Black JRM, et al. LBA55. An ultra-sensitive and specific ctDNA assay provides novel pre-operative disease stratification in early stage lung cancer. Ann Oncol. 2023;34(Suppl):S1294-S1294.

*Data listed is longitudinal data. Longitudinal data refers to a minimum of two MRD tests that are performed post-surgery.

This is data-driven precision medicine

Stay up to date on important product information and learn more about ordering.